A new generation M^pro inhibitor with potent activity against SARS-CoV-2 Omicron variants.

ABSTRACT: Emerging SARS-CoV-2 variants, particularly the Omicron variant and its sublineages, continually threaten the global public health. Small molecule antivirals are an effective treatment strategy to fight against the virus. However, the first-generation antivirals either show limited clinical efficacy and/or have some defects in pharmacokinetic (PK) properties. Moreover, with increased use of these drugs across the globe, they face great pressure of drug resistance. We herein present the discovery and characterization of a new generation antiviral drug candidate (SY110), which is a potent and selective inhibitor of SARS-CoV-2 main protease (M^pro). This compound displayed potent in vitro antiviral activity against not only the predominant SARS-CoV-2 Omicron sublineage BA.5, but also

SUBMITTER: Huang C 

PROVIDER: S-EPMC10018608 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature